title: Sulfasalazine for brain cancer fits.
abstract: Recent research has identified an important role for a cystine-glutamate antiporter (system Xc) in the biology of malignant brain tumors. This transporter is effectively inhibited by sulfasalazine, a drug widely used to treat a number of chronic inflammatory conditions such as Crohn's disease. Preclinical data show that sulfasalazine is an effective inhibitor of tumor growth and tumor-associated seizures. These studies suggest that the cystine-glutamate antiporter is a valuable drug target for which tumor-specific drugs can be generated. In the meantime, sulfasalazine may be considered as adjuvant treatment for malignant gliomas.
authors.forename: Harald
authors.initials: H
authors.lastname: Sontheimer
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Bridges
mesh_terms: D027182:Amino Acid Transport System y+ / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D005910:Glioma / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D012460:Sulfasalazine / Q000627:therapeutic use*
chemical_list: D027182:Amino Acid Transport System y+; D000927:Anticonvulsants; D000970:Antineoplastic Agents; D012460:Sulfasalazine